Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation for misleading statements regarding its financial performance and project costs during the Class Period from February 18, 2025, to July 31, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Fluor made false and misleading statements about the costs associated with several major projects, including the Gordie Howe International Bridge and various Texas highways, due to subcontractor errors, price increases, and scheduling delays [5]. - It is alleged that these issues, along with reduced customer capital spending and economic uncertainty, negatively impacted Fluor's business and financial results [5]. - The lawsuit asserts that Fluor's financial guidance for 2025 was unreliable and that the company's risk mitigation strategies were overstated [5]. Group 2: Investor Information - Investors who purchased Fluor securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by November 14, 2025, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period†). Jasper is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigat. ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, alleging misleading statements regarding the company's drug application process [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Savara made false statements about the MOLBREEVI Biologics License Application (BLA), indicating it lacked sufficient information for FDA approval [5]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay Savara's submission timeline and increase the need for additional capital [5]. - The lawsuit asserts that these misleading statements caused investors to suffer damages when the true information became public [5]. Group 2: Class Action Participation - Investors who purchased Savara securities during the class period may be entitled to compensation without upfront fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form online or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 7, 2025, to represent the interests of the class members [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Group 1 - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR) [1] - Investors who own shares of Danaher stock are encouraged to seek more information through Rosen Law Firm's website or contact them directly [1] Group 2 - Rosen Law Firm has a strong track record in securities class actions and shareholder derivative litigation, having achieved significant settlements for investors [2] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [2] - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [2]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fiserv, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Fiserv common stock purchase is from July 24, 2024, to July 22, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by September 22, 2025, to serve as lead plaintiff [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Fiserv made false and misleading statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older Payeezy platform [4]. - It is claimed that Clover's revenue growth was artificially inflated by these forced migrations, masking a slowdown in new merchant business [4]. - The lawsuit further alleges that many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's growth metrics [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fly-E Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Fly-E Group, Inc. securities is from July 15, 2025, to August 14, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Fly-E Group provided misleading statements regarding the safety of its lithium battery, which negatively impacted E-vehicle sales revenue [4]. - Despite optimistic long-term projections, Fly-E's sales continued to decline, and operating expenses increased, leading to a failure in meeting revenue forecasts [4]. - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about the lead plaintiff deadline for a class action lawsuit related to the company's initial public offering and subsequent securities purchases [1]. Group 1: Class Action Details - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Fluor Corporation (NYSE: FLR) between February 18, 2025 and July 31, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 14, 2025. SO WHAT: If you purchased Fluor securities during the Class ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Savara Inc. securities, alleging misleading statements regarding the company's Biologics License Application for MOLBREEVI, which may have impacted investors negatively during the specified Class Period from March 7, 2024, to May 23, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Savara Inc. made false and misleading statements about the MOLBREEVI Biologics License Application, indicating that it lacked sufficient information for FDA approval [5]. - The lawsuit suggests that the delay in regulatory approval for MOLBREEVI increased the likelihood that Savara would need to raise additional capital, which was not disclosed to investors [5]. - Investors who purchased Savara securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can submit their information through the Rosen Law Firm's website or contact them directly for more details [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must move the Court by November 7, 2025, to serve in this capacity [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased CTO Realty Growth, Inc. securities between February 18, 2021, and June 24, 2025, of the upcoming lead plaintiff deadline on October 7, 2025 [1]. Group 1: Class Action Details - Investors who purchased CTO Realty securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 7, 2025 [3]. - The lawsuit alleges that CTO Realty Growth made false and misleading statements regarding the sustainability of its dividends and the profitability of its Ashford Lane property, leading to overstated business and financial prospects [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].